Supreme Court pauses lower court ruling on mifepristone telemedicine access
The US Supreme Court has issued an administrative stay that temporarily restores nationwide access to the abortion pill via telehealth, halting a decision by the 5th Circuit Court of Appeals that required in-person clinician visits.
The US Supreme Court has issued an interim order temporarily reinstating the rule allowing the abortion pill mifepristone to be prescribed through telemedicine and dispensed by mail. This decision pauses a ruling by the 5th US Circuit Court of Appeals, which had mandated an in-person clinician visit following a legal challenge brought by the state of Louisiana. The move effectively restores access to the medication nationwide while broader legal challenges regarding Food and Drug Administration regulations continue to play out.
Justice Samuel Alito issued the administrative stay on Monday, designating him to oversee emergency matters for a specific group of states that includes Louisiana. The order specifically halts the 5th Circuit Court of Appeals' May 1 decision, ensuring that the older federal rule requiring physical visits does not take effect during this period. Alito ordered Louisiana to respond to the drugmakers' requests by Thursday, with the interim stay remaining in effect for one week until May 11.
The Supreme Court's action provides time for the justices to review emergency requests submitted by two manufacturers of mifepristone, Danco Laboratories and GenBioPro. The manufacturers argue that the drug can be safely provided via telehealth and the mail, seeking to maintain the 2023 regulation that eased access. The court is expected to either extend the interim stay or formally decide on the manufacturers' requests by the May 11 deadline.
This development places the contentious issue of abortion rights back in front of the justices, who must confront another effort by opponents to scale back access to the medication. The case arises against the backdrop of the court's 2022 ruling that overturned the 1973 Roe v Wade precedent, a decision that has prompted thirteen states to enact near-total bans on the procedure. Louisiana sued the FDA last year, claiming that a rule adopted during the previous administration is illegal and undermines the state's abortion ban.
Political reactions to the interim order remain divided. Senator Chuck Schumer welcomed the decision but noted that the fight to prevent a national abortion ban is just beginning. Conversely, Senator Josh Hawley cited disputed findings on health risks and urged Congress to ban mifepristone completely for use in abortion. The American Civil Liberties Union characterised the decision as a positive short-term development for reproductive freedom.
The ongoing legal battle highlights the friction between state-level restrictions and federal regulatory frameworks. While the current order restores access, the underlying dispute over FDA regulations and the scope of abortion rights continues to dominate the political landscape as the November congressional elections approach.
